News

Traumatic brain injuries come with an amplified risk for developing dementia, but a new therapeutic target and a potential immunotherapy have been identified.

A new study offers an explanation and suggests a more effective approach to treatment of epilepsy. They found a previously overlooked region of the hippocampus, the fasciola cinereum, appears to be involved in instigating and propagating seizures.

In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells (VST) can effectively treat immunocompromised pediatric patients, far surpassing the current standard of care.

Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

Recently approved Alzheimer's drugs work by tagging amyloid plaques for clearance by the brain's microglia. Washington University School of Medicine in St. Louis researchers are developing an alternative approach, using a homemade antibody to directly mobilize microglia.

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Salk scientists observe cannabinol's neuroprotective properties in fruit flies and identify cannabinol analogs that could serve as promising future therapeutics for traumatic brain injury, Alzheimer's, and Parkinson's.

Antipsychotic use in people with dementia is associated with elevated risks of a wide range of serious adverse outcomes including stroke, blood clots, heart attack, heart failure, fracture, pneumonia, and acute kidney injury, compared with non-use.

Researchers have discovered toxic protein particles, shaped like umbrellas, that soil bacteria known as Streptomyces secrete to squelch competitors, especially others of their own species.

University of Cambridge researchers have harnessed the power of artificial intelligence (AI) to speed up the screening of new drugs to treat Parkinson’s disease.